Innate Pharma à l’AACR 2019 : nouvelles données sur la prochaine génération d’immunothérapies des cancers
April 01, 2019 01:00 ET
|
INNATE PHARMA
INNATE PHARMA A L’AACR 2019 : NOUVELLES DONNÉES SUR LA PROCHAINE GÉNÉRATION D’IMMUNOTHÉRAPIES DES CANCERS Nouvelles données précliniques sur IPH5201 (anti-CD39) et IPH5301 (anti-CD73) ciblant la...
Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting
April 01, 2019 01:00 ET
|
INNATE PHARMA
INNATE PHARMA HIGHLIGHTS NEXT GENERATION OF CANCER IMMUNOTHERAPIES AT THE AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) 2019 ANNUAL MEETING New preclinical data highlights IPH5201 (anti-CD39) and...
Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products
December 03, 2018 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces FDA Fast Track Designation for ProTmune™
June 20, 2016 08:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer
May 17, 2016 08:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy
May 16, 2016 08:01 ET
|
Fate Therapeutics, Inc.
Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota Program to be Presented Today at Innate Killer Summit 2016 SAN DIEGO, May 16,...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016
May 02, 2016 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, May 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016
February 25, 2016 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...